Literature DB >> 227

Human and monkey prolactin and growth hormone: separation of polymorphic forms by isoelectric focusing.

B C Hummel, G M Brown, P Hwang, H G Friesen.   

Abstract

The feasibility of using isoelectric focusing for the separation of primate pituitary growth hormone from prolactin and for the characterization of polymorphic forms of these hormones was explored. In a pH 3--10 gradient, extracts of both human and cynomolgus monkey pituitaries were each resolved into 4 growth hormone components and at least 3 prolactin components, as shown by radioimmunoassay. In narrower gradients (of 2--3 pH units) greater resolution was achieved; the principal growth hormone components were well separated from the principal prolactin components but there was overlapping of some minor components. A partially purified human prolactin preparation was found to contain 4 prolactin components, one of which had a prolactin/growth hormone ratio of 760. Clinical grade human growth hormone was also resolved into at least 5 prolactin and 5 growth hormone components, many of which had higher pI values than those found in pituitary extract. Under the conditions used, both growth hormone and prolactin were found to be polymorphic with respect to isoelectric point. Some of the human prolactin components were found to contain less than 0.2% growth hormone by radioimmunoassay. Monkey growth hormone containing 0.01% prolactin was isolated. These findings demonstrate that isoelectric focusing is useful for the preparation of both growth hormone and prolactin which are essentially free of one another. Furthermore, the polymorphic forms were repeatedly found in preparations obtained by several methods and from 2 different species, suggesting that these forms are not artifacts.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 227     DOI: 10.1210/endo-97-4-855

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  62 in total

1.  Usefulness of a tilt training program for the prevention of refractory neurocardiogenic syncope in adolescents: A controlled study.

Authors:  E Di Girolamo; C Di Iorio; L Leonzio; P Sabatini; A Barsotti
Journal:  Circulation       Date:  1999-10-26       Impact factor: 29.690

2.  Formal analysis of the optimal duration of tilt testing for the diagnosis of neurally mediated syncope.

Authors:  K M Stein; D J Slotwiner; S Mittal; M Scheiner; S M Markowitz; B B Lerman
Journal:  Am Heart J       Date:  2001-02       Impact factor: 4.749

3.  Permanent cardiac pacing versus medical treatment for the prevention of recurrent vasovagal syncope: a multicenter, randomized, controlled trial.

Authors:  F Ammirati; F Colivicchi; M Santini
Journal:  Circulation       Date:  2001-07-03       Impact factor: 29.690

4.  'The Italian Protocol': a simplified head-up tilt testing potentiated with oral nitroglycerin to assess patients with unexplained syncope.

Authors:  A Bartoletti; P Alboni; F Ammirati; M Brignole; A Del Rosso; G Foglia Manzillo; C Menozzi; A Raviele; R Sutton
Journal:  Europace       Date:  2000-10       Impact factor: 5.214

5.  Effect of etilefrine in preventing syncopal recurrence in patients with vasovagal syncope: a double-blind, randomized, placebo-controlled trial. The Vasovagal Syncope International Study.

Authors:  A Raviele; M Brignole; R Sutton; P Alboni; P Giani; C Menozzi; A Moya
Journal:  Circulation       Date:  1999-03-23       Impact factor: 29.690

6.  Head-up tilt testing potentiated with oral nitroglycerin: a randomized trial of the contribution of a drug-free phase and a nitroglycerin phase in the diagnosis of neurally mediated syncope.

Authors:  A Bartoletti; G Gaggioli; C Menozzi; N Bottoni; A Del Rosso; R Mureddu; G Musso; G Foglia-Manzillo; B Bonfigli; M Brignole
Journal:  Europace       Date:  1999-07       Impact factor: 5.214

7.  New classification of haemodynamics of vasovagal syncope: beyond the VASIS classification. Analysis of the pre-syncopal phase of the tilt test without and with nitroglycerin challenge. Vasovagal Syncope International Study.

Authors:  M Brignole; C Menozzi; A Del Rosso; S Costa; G Gaggioli; N Bottoni; P Bartoli; R Sutton
Journal:  Europace       Date:  2000-01       Impact factor: 5.214

8.  Dual-chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope : pacemaker versus no therapy: a multicenter randomized study. The Vasovagal Syncope International Study (VASIS) Investigators.

Authors:  R Sutton; M Brignole; C Menozzi; A Raviele; P Alboni; P Giani; A Moya
Journal:  Circulation       Date:  2000-07-18       Impact factor: 29.690

9.  Provocation of neurocardiogenic syncope by clomipramine administration during the head-up tilt test in vasovagal syndrome.

Authors:  G N Theodorakis; M Markianos; E Zarvalis; E G Livanis; P Flevari; D T Kremastinos
Journal:  J Am Coll Cardiol       Date:  2000-07       Impact factor: 24.094

10.  Misdiagnosis of epilepsy: many seizure-like attacks have a cardiovascular cause.

Authors:  A Zaidi; P Clough; P Cooper; B Scheepers; A P Fitzpatrick
Journal:  J Am Coll Cardiol       Date:  2000-07       Impact factor: 24.094

View more
  3 in total

Review 1.  Paradigm-shifters: phosphorylated prolactin and short prolactin receptors.

Authors:  KuangTzu Huang; Eric Ueda; YenHao Chen; Ameae M Walker
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

2.  Hydrophobic-interaction chromatography and anion-exchange chromatography in the presence of acetonitrile. A two-step purification method for human prolactin.

Authors:  S C Hodgkinson; P J Lowry
Journal:  Biochem J       Date:  1981-12-01       Impact factor: 3.857

Review 3.  Prolactin receptor antagonists.

Authors:  C B Kuo; D Coss; A M Walker
Journal:  Endocrine       Date:  1998-10       Impact factor: 3.925

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.